Ranbaxy to sell bio-generic osteoporosis drug

Ranbaxy Laboratories today announced the launch of Bonista - teriparatide injection (recombinant human parathyroid hormone) - for the treatment of osteoporosisin in association with Virchow Biotech, Hyderabad,

Ranbaxy is the first company to launch this bio-generic product in the world.

"Ranbaxy has a number of new products in its pipeline including Bonista for Osteoporosis patients who are normally treated by orthopaedics and gynaecologists. Bonista is also a classic example of our endeavour to offer quality bio-generic options to doctors and an affordable and efficacious product to patients," said Sanjeev I Dani, senior vice president & regional director (Asia & CIS), Ranbaxy.